{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T07:31:21Z","timestamp":1767598281505,"version":"build-2065373602"},"reference-count":124,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Dermatologic pathologies are the fourth most common cause of non-fatal disease worldwide; however, they produce a psychosocial, economic, and occupational impact equal to or greater than other chronic conditions. The most prevalent are actinic keratosis, followed by basal-cell carcinoma, in a lesser proportion acne vulgaris, psoriasis, and hidradenitis suppurativa, among others, and more rarely dermatitis herpetiformis. To treat actinic keratosis and basal-cell carcinoma, 5-fluorouracil (5-FU) 0.5% is administered topically with good results, although in certain patients it produces severe toxicity. On the other hand, dapsone is a drug commonly used in inflammatory skin conditions such as dermatitis herpetiformis; however, it occasionally causes hemolytic anemia. Additionally, biologic drugs indicated for the treatment of moderate-to-severe psoriasis and hidradenitis suppurativa have proved to be effective and safe; nevertheless, a small percentage of patients do not respond to treatment with biologics in the long term or they are ineffective. This interindividual variability in response may be due to alterations in genes that encode proteins involved in the pathologic environment of the disease or the mechanism of action of the medication. Pharmacogenetics studies the relationship between genetic variations and drug response, which is useful for the early identification of non-responsive patients and those with a higher risk of developing toxicity upon treatment. This review describes the pharmacogenetic recommendations with the strongest evidence at present for the treatments used in dermatology, highlighting those included in clinical practice guides. Currently, we could only find pharmacogenetic clinical guidelines for 5-FU. However, the summary of product characteristics for dapsone contains a pharmacogenetic recommendation from the United States Food and Drug Administration. Finally, there is an enormous amount of information from pharmacogenetic studies in patients with dermatologic pathologies (mainly psoriasis) treated with biologic therapies, but they need to be validated in order to be included in clinical practice guides.<\/jats:p>","DOI":"10.3390\/ph14090905","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T21:47:38Z","timestamp":1630964858000},"page":"905","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Application of Pharmacogenetic Markers in the Treatment of Dermatologic Pathologies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-5766","authenticated-orcid":false,"given":"Cristina","family":"Membrive Jim\u00e9nez","sequence":"first","affiliation":[{"name":"Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"P\u00e9rez Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain"},{"name":"Center of Biomedical Research, Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology \u201cJos\u00e9 Mataix\u201d, University of Granada, Avda. del Conocimiento s\/n., Armilla, 18016 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"S\u00e1nchez Mart\u00edn","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayleth","family":"Vieira Maroun","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Arias Santiago","sequence":"additional","affiliation":[{"name":"Dermatology Service, University Hospital Virgen de las Nieves, 18016 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7999-0881","authenticated-orcid":false,"given":"Mar\u00eda Carmen","family":"Ram\u00edrez Tortosa","sequence":"additional","affiliation":[{"name":"Center of Biomedical Research, Department of Biochemistry and Molecular Biology II, Institute of Nutrition and Food Technology \u201cJos\u00e9 Mataix\u201d, University of Granada, Avda. del Conocimiento s\/n., Armilla, 18016 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Jim\u00e9nez Morales","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, 18014 Granada, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"ref_1","first-page":"271","article-title":"Skin conditions in primary care: An analysis of referral demand","volume":"105","author":"Garrido","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"ref_2","unstructured":"Alonso, P. (2021, February 15). Atlas de Dermatolog\u00eda del Pie: Editorial medica Panamericana. Available online: https:\/\/books.google.com.ec\/books?id=Sji16aQ9XwUC&printsec=frontcover#v=onepage&q&f=false."},{"key":"ref_3","first-page":"416","article-title":"Outpatient Dermatological Diagnoses in Spain: Results from the National DIADERM Random Sampling Project","volume":"109","author":"Gilaberte","year":"2018","journal-title":"Actas Dermosifiliogr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.16248","article-title":"Prevalence of skin disease in a population-based sample of adults from five European countries","volume":"178","author":"Svensson","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_5","first-page":"e1","article-title":"Principios de la terap\u00e9utica m\u00e9dica dermatol\u00f3gica","volume":"332","year":"2012","journal-title":"Pediatr. Integral"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Aceituno, E., Martos-Cabrera, L., Ovejero-Benito, M.C., Reolid, A., Abad-Santos, F., and Daud\u00e9n, E. (2020). Pharmacogenetics Update on Biologic Therapy in Psoriasis. Medicina, 56.","DOI":"10.3390\/medicina56120719"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-017-0322-9","article-title":"Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis","volume":"19","author":"Reolid","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.drudis.2020.01.023","article-title":"Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine","volume":"25","author":"Mehta","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_9","unstructured":"European Medicines Agency (2021). EMA Recommendations on DPD Testing Prior to Treatment with Fluorouracil, Capecitabine, Tegafur and Flucytosine, European Medicines Agency. EMA\/367286\/2020 J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fphar.2020.00969","article-title":"Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions","volume":"11","author":"Chang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.12788\/j.sder.2019.009","article-title":"Pharmacogenomics in dermatology: Tools for understanding gene-drug associations","volume":"38","author":"Daneshjou","year":"2019","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_12","first-page":"501","article-title":"Drug Hypersensitivity","volume":"115","author":"Proksch","year":"2018","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.14852","article-title":"Current perspective on actinic keratosis: A review","volume":"177","author":"Siegel","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ijd.14147","article-title":"Actinic keratosis\u2014Review for clinical practice","volume":"58","author":"Pantoja","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ad.2017.05.014","article-title":"Prevalence of Actinic Keratosis in Different Regions of Spain: The EPIQA Study","volume":"109","author":"Ferrandiz","year":"2018","journal-title":"Actas Dermosifiliogr."},{"key":"ref_16","first-page":"492","article-title":"Actinic keratosis: New concept and therapeutic update","volume":"49","year":"2017","journal-title":"Aten Primaria"},{"key":"ref_17","first-page":"385","article-title":"Basal cell carcinoma: Clinical and pathological features","volume":"150","author":"Chimenti","year":"2015","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_18","first-page":"291","article-title":"Diagnosis and Treatment of Basal Cell Carcinoma in Specialized Dermatology Units: A Clinical Practice Guideline","volume":"111","year":"2020","journal-title":"Actas Dermosifiliogr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/jamadermatol.2013.368","article-title":"Basal cell carcinoma","volume":"149","author":"Sobanko","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Fania, L., Didona, D., Morese, R., Campana, I., Coco, V., Di Pietro, F.R., Ricci, F., Pallotta, S., Candi, E., and Abeni, D. (2020). Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 8.","DOI":"10.3390\/biomedicines8110449"},{"key":"ref_21","first-page":"167","article-title":"Basal cell carcinoma: Pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management","volume":"88","author":"Marzuka","year":"2015","journal-title":"Yale J. Biol. Med."},{"key":"ref_22","first-page":"1","article-title":"Dermatitis herpetiformis","volume":"18","author":"Plotnikova","year":"2013","journal-title":"Skin Therapy Lett."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/ced.13992","article-title":"Dermatitis herpetiformis","volume":"44","author":"Salmi","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/1744666X.2020.1719833","article-title":"Epidemiology of major chronic inflammatory immune-related skin diseases in 2019","volume":"16","author":"Pezzolo","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"adv00056","DOI":"10.2340\/00015555-3401","article-title":"Current Concepts of Dermatitis Herpetiformis","volume":"100","author":"Salmi","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1590\/abd1806-4841.20142966","article-title":"Dermatitis herpetiformis: Pathophysiology, clinical presentation, diagnosis and treatment","volume":"89","author":"Clarindo","year":"2014","journal-title":"An. Bras. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jaad.2020.02.044","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamadermatol.2018.3442","article-title":"Association Between Psoriasis and Sexual and Erectile Dysfunction in Epidemiologic Studies: A Systematic Review","volume":"155","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of Psoriasis: A comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J. Autoimmun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.molimm.2014.12.014","article-title":"Genetic and epigenetic basis of psoriasis pathogenesis","volume":"64","author":"Chandra","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13554","DOI":"10.1111\/jcmm.15742","article-title":"Overview of the molecular determinants contributing to the expression of Psoriasis and Psoriatic Arthritis phenotypes","volume":"24","author":"Caputo","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.rdc.2015.07.013","article-title":"Etiology and Pathogenesis of Psoriasis","volume":"41","author":"Boehncke","year":"2015","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.13542","article-title":"Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology","volume":"30","author":"Puig","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.03.033","article-title":"Long term safety of nine systemic medications for psoriasis: A cohort study using the Biobadaderm Registry","volume":"83","author":"Dauden","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_36","first-page":"114","article-title":"What is hidradenitis suppurativa?","volume":"63","author":"Lee","year":"2017","journal-title":"Can. Fam. Physician."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000493465","article-title":"Adolescent-Onset Hidradenitis Suppurativa: Prevalence, Risk Factors and Disease Features","volume":"235","year":"2019","journal-title":"Dermatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1159\/000513044","article-title":"Implications of Hidradenitis Suppurativa Phenotypes in Cardiovascular Risk and Treatment Decisions: A Retrospective Cohort Study","volume":"237","year":"2021","journal-title":"Dermatology"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cuenca-Barrales, C., and Molina-Leyva, A. (2020). Sexuality in Patients with Hidradenitis Suppurativa: Beliefs, Behaviors and Needs. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17238808"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0001-7310(08)74631-3","article-title":"Practical management of hidradenitis suppurativa","volume":"99","author":"Pedraz","year":"2008","journal-title":"Actas Dermosifiliogr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jid.2019.06.152","article-title":"A Genetic Variant in the BCL2 Gene Associates with Adalimumab Response in Hidradenitis Suppurativa Clinical Trials and Regulates Expression of BCL2","volume":"140","author":"Liu","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11154-016-9328-5","article-title":"Evidence-based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa","volume":"17","author":"Gulliver","year":"2016","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1001\/jama.2017.16691","article-title":"Hidradenitis Suppurativa: Advances in Diagnosis and Treatment","volume":"318","author":"Saunte","year":"2017","journal-title":"JAMA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_45","first-page":"e12885","article-title":"Adalimumab every other week combined with dexamethasone pulses for the treatment of refractory hidradenitis suppurativa","volume":"32","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/jdv.16726","article-title":"Sexual impairment in patients with hidradenitis suppurativa: A systematic review","volume":"35","author":"Szepietowski","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","unstructured":"(2017). 5-Fluorouracil 05% and Salicylic Acid 100% (Actikerall), CADTH Common Drug Reviews."},{"key":"ref_49","unstructured":"Casale, J., and Crane, J.S. (2021, February 18). Fluorouracil. StatPearls. Treasure Island (FL)2020, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK549808\/."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1756-9966-27-54","article-title":"Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy","volume":"27","author":"Amstutz","year":"2008","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: A prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"23192","DOI":"10.1016\/S0021-9258(17)31638-1","article-title":"cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria","volume":"269","author":"Yokota","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00403-013-1409-7","article-title":"Dapsone in dermatology and beyond","volume":"306","author":"Wozel","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40257-016-0242-0","article-title":"Dapsone 7.5% Gel: A Review in Acne Vulgaris","volume":"18","author":"Deeks","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_56","unstructured":"(2021, February 17). Allergan Announces FDA Approval of Aczone (dapsone) Gel, 7.5% for Treatment of Acne Vulgaris. Available online: https:\/\/www.prnewswire.com\/news-releases\/allergan-announces-fda-approval-of-aczone-dapsone-gel-75-for-treatment-of-acne-vulgaris-300226540.html."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D330M4B5KR","article-title":"Dapsone","volume":"8","author":"Wolf","year":"2002","journal-title":"Dermatol. Online J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2165\/00003088-198611040-00003","article-title":"Clinical pharmacokinetics of dapsone","volume":"11","author":"Zuidema","year":"1986","journal-title":"Clin. Pharmacokinet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/1475-2875-11-139","article-title":"Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria","volume":"11","author":"Machevo","year":"2012","journal-title":"Malar. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jid.2018.02.004","article-title":"The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions","volume":"138","author":"Chen","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/clpt.2014.97","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype","volume":"96","author":"Relling","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12936-019-2688-z","article-title":"An update on glucose-6-phosphate dehydrogenase deficiency in children from Brazzaville, Republic of Congo","volume":"18","author":"Peko","year":"2019","journal-title":"Malar. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1001\/archdermatol.2008.518","article-title":"Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris","volume":"144","author":"Piette","year":"2008","journal-title":"Arch. Dermatol."},{"key":"ref_64","unstructured":"FDA (2021, February 20). Table of Pharmacogenomic Biomarkers in Drug Labelin, Available online: https:\/\/www.fda.gov\/drugs\/science-and-research-drugs\/table-pharmacogenomic-biomarkers-drug-labeling."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1074-7613(01)00197-2","article-title":"Genetic and functional relationships between MHC and NK receptor genes","volume":"15","author":"Trowsdale","year":"2001","journal-title":"Immunity"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamadermatol.2017.6484","article-title":"Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-analysis","volume":"154","author":"Tangamornsuksan","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1111\/jdv.15047","article-title":"Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany","volume":"32","author":"Augustin","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-Term Efficacy and Safety of IL-17, IL-12\/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1080\/21645515.2017.1356498","article-title":"Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis","volume":"13","author":"Jeon","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Sawyer, L.M., Malottki, K., Sabry-Grant, C., Yasmeen, N., Wright, E., Sohrt, A., Borg, E., and Warren, R.B. (2019). Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0220868"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jaad.2020.03.073","article-title":"Treatment of erythrodermic psoriasis with biologics: A systematic review","volume":"83","author":"Carrasquillo","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e12946","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Petrovic","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/jdv.15277","article-title":"Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response","volume":"33","author":"Sawyer","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjd.15830","article-title":"Risk of cancer in patients with psoriasis on biological therapies: A systematic review","volume":"178","author":"Peleva","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s13555-020-00373-z","article-title":"Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence","volume":"10","author":"Wu","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40257-015-0131-y","article-title":"Immunogenicity of biologic treatments for psoriasis: Therapeutic consequences and the potential value of concomitant methotrexate","volume":"16","author":"Farhangian","year":"2015","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Membrive Jim\u00e9nez, C., P\u00e9rez Ram\u00edrez, C., S\u00e1nchez Mart\u00edn, A., Vieira Maroun, S., Arias Santiago, S.A., Ram\u00edrez Tortosa, M.D.C., and Jim\u00e9nez Morales, A. (2021). Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11040293"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2019.0098","article-title":"Association of HLA-C*06:02 Status with Differential Response to Ustekinumab in Patients with Psoriasis: A Systematic Review and Meta-analysis","volume":"155","author":"Hannink","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000441719","article-title":"IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis","volume":"232","author":"Galluzzo","year":"2016","journal-title":"Dermatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40291-017-0261-4","article-title":"HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study","volume":"21","author":"Talamonti","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ced.12323","article-title":"Genetic markers of treatment response to tumour necrosis factor-\u03b1 inhibitors in the treatment of psoriasis","volume":"39","author":"Ryan","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3389\/fimmu.2018.00954","article-title":"Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis","volume":"9","author":"Prinz","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/pgs-2017-0014","article-title":"Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis","volume":"18","author":"Belmonte","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_86","first-page":"70","article-title":"New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Cabaleiro","year":"2018","journal-title":"Pharm. J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40291-016-0198-z","article-title":"A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-\u03b1 and Anti-IL-12\/23 Agents","volume":"20","author":"Masouri","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.12425","article-title":"The relationship between tumour necrosis factor (TNF)-\u03b1 promoter and IL12B\/IL-23R genes polymorphisms and the efficacy of anti-TNF-\u03b1 therapy in psoriasis: A case-control study","volume":"169","author":"Gallo","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjd.15387","article-title":"Role of the HLA-C*06 allele in clinical response to ustekinumab: Evidence from real life in a large cohort of European patients","volume":"177","author":"Talamonti","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2217\/pgs.15.90","article-title":"Association between TNF-\u03b1 (-308 A\/G, -238 A\/G, -857 C\/T) polymorphisms and responsiveness to TNF-\u03b1 blockers in spondyloarthropathy, psoriasis and Crohn\u2019s disease: A meta-analysis","volume":"16","author":"Song","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_91","first-page":"71","article-title":"Gene polymorphisms as predictors of response to biological therapies in psoriasis patients","volume":"113 Pt A","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bjd.12331","article-title":"Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B\/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12\/23 blocker ustekinumab","volume":"169","author":"Talamonti","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.15005","article-title":"Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis","volume":"176","author":"Coenen","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_94","first-page":"e175","article-title":"Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis","volume":"33","author":"Reolid","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_95","first-page":"494","article-title":"Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis","volume":"18","author":"Loft","year":"2018","journal-title":"Pharm. J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/FPC.0b013e32834e5e7b","article-title":"-174G\/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-\u03b1 blockers","volume":"22","author":"Bianchi","year":"2012","journal-title":"Pharm. Genom."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00296-012-2501-6","article-title":"IL-23A, IL-23R, IL-17A and IL-17R polymorphisms in different psoriatic arthritis clinical manifestations in the northern Italian population","volume":"33","author":"Catanoso","year":"2013","journal-title":"Rheumatol. Int."},{"key":"ref_99","first-page":"76","article-title":"IL17RA gene variants and anti-TNF response among psoriasis patients","volume":"18","author":"Batalla","year":"2018","journal-title":"Pharm. J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jdermsci.2015.06.011","article-title":"Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17E rs79877597 and Psoriasis in a Spanish cohort","volume":"80","author":"Batalla","year":"2015","journal-title":"J. Dermatol. Sci."},{"key":"ref_101","first-page":"336","article-title":"Paradoxical psoriasiform reactions to anti-TNF\u03b1 drugs are associated with genetic polymorphisms in patients with psoriasis","volume":"16","author":"Cabaleiro","year":"2016","journal-title":"Pharm. J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/bjd.12192","article-title":"Predicting response to anti-TNF-alpha treatment in Hidradenitis suppurativa","volume":"168","author":"Jemec","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjd.12105","article-title":"Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa","volume":"168","author":"Savva","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Liu, M., Degner, J., Davis, J.W., Idler, K.B., Nader, A., Mostafa, N.M., and Waring, J.F. (2018). Identification of HLA-DRB1 association to adalimumab immunogenicity. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195325"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.3390\/curroncol28040213","article-title":"Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far?","volume":"28","author":"Bennardo","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5070\/D3244039360","article-title":"Topical application of 5-fluorouracil 5 percent cream associated with severe neutropenia: Discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil","volume":"24","author":"Cohen","year":"2018","journal-title":"Dermatol. Online J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/j.1524-4725.2012.02511.x","article-title":"Systemic toxicity from occlusive therapy with topical 5-fluorouracil: A case report and review of the literature","volume":"38","author":"Sargen","year":"2012","journal-title":"Dermatol. Surg."},{"key":"ref_108","first-page":"2006","article-title":"Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil","volume":"5","author":"Johnson","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s40800-017-0068-6","article-title":"Life-Threatening Reaction with Topical 5-Fluorouracil","volume":"5","author":"Kishi","year":"2018","journal-title":"Drug Saf. Case Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2165\/11536520-000000000-00000","article-title":"Medications and glucose-6-phosphate dehydrogenase deficiency: An evidence-based review","volume":"33","author":"Youngster","year":"2010","journal-title":"Drug Saf."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/FPC.0b013e32834eb313","article-title":"PharmGKB summary: Very important pharmacogene information for G6PD","volume":"22","author":"McDonagh","year":"2012","journal-title":"Pharm. Genom."},{"key":"ref_112","unstructured":"PharmGKB (2021, March 15). Available online: https:\/\/www.pharmgkb.org\/."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/hmg\/ddn245","article-title":"Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis","volume":"17","author":"Maxwell","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/art.23092","article-title":"Influence of -308 A\/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis","volume":"57","author":"Guis","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","article-title":"The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients","volume":"46","author":"Seitz","year":"2007","journal-title":"Rheumatology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/ard.62.6.526","article-title":"Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis","volume":"62","author":"Padyukov","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3109\/s10165-012-0699-5","article-title":"Association between tumor necrosis factor-\u03b1 (TNF-\u03b1) promoter -308 G\/A and response to TNF-\u03b1 blockers in rheumatoid arthritis: A meta-analysis","volume":"23","author":"Zeng","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"ref_118","first-page":"161","article-title":"TNF-alpha-308 G\/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: A systematic review and meta-analysis","volume":"9","author":"Roslin","year":"2009","journal-title":"Pharm. J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00296-006-0175-7","article-title":"Association of TNF-alpha -308 G\/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: A meta-analysis","volume":"27","author":"Lee","year":"2006","journal-title":"Rheumatol. Int."},{"key":"ref_120","first-page":"2059513120941704","article-title":"The role of pharmacogenetics in keloid scar treatment: A literature review","volume":"6","author":"Searle","year":"2020","journal-title":"Scars Burns Heal."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2217\/pgs-2018-0192","article-title":"NR3C1, ABCB1, TNF and CYP2C19 polymorphisms association with the response to the treatment of erythema nodosum leprosum","volume":"20","author":"Nazario","year":"2019","journal-title":"Pharmacogenomics"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/bjc.2018.9","article-title":"PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC","volume":"118","author":"Marconcini","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/jamia\/ocy005","article-title":"Implementing pharmacogenomics decision support across seven European countries: The Ubiquitous Pharmacogenomics (U-PGx) project","volume":"25","author":"Blagec","year":"2018","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/cpt.630","article-title":"The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems","volume":"102","author":"Luzum","year":"2017","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/9\/905\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:57:32Z","timestamp":1760165852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/9\/905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":124,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["ph14090905"],"URL":"https:\/\/doi.org\/10.3390\/ph14090905","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2021,9,6]]}}}